BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD. Financials Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
Equities
688621
CNE100005139
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.4 CNY | +0.59% |
|
+0.55% | -29.18% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 9,728 | 8,192 | 7,812 | 5,533 | - | - |
| Enterprise Value (EV) 1 | 9,728 | 8,192 | 7,812 | 5,533 | 5,533 | 5,533 |
| P/E ratio | 80.5 x | 52.5 x | 40.3 x | 19.9 x | 12.5 x | 12.6 x |
| Yield | - | 0.59% | 0.24% | 1.4% | 1.84% | 2.45% |
| Capitalization / Revenue | - | 12.1 x | 8.19 x | 4.39 x | 3.35 x | 2.56 x |
| EV / Revenue | - | 12.1 x | 8.19 x | 4.39 x | 3.35 x | 2.56 x |
| EV / EBITDA | - | 40.9 x | 33 x | 15.6 x | 11.4 x | 9.22 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | 9.14 x | 7.49 x | 4.37 x | 2.96 x | 3.02 x |
| Nbr of stocks (in thousands) | 112,000 | 112,000 | 112,000 | 112,000 | - | - |
| Reference price 2 | 86.86 | 73.14 | 69.75 | 49.40 | 49.40 | 49.40 |
| Announcement Date | 2/27/22 | 2/9/23 | 2/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 347.4 | - | 676.6 | 953.9 | 1,260 | 1,654 | 2,161 |
| EBITDA 1 | - | - | 200.3 | 236.7 | 354.5 | 484.7 | 600 |
| EBIT 1 | - | - | 169.3 | 201.8 | 317.3 | 427.3 | 485 |
| Operating Margin | - | - | 25.02% | 21.16% | 25.19% | 25.84% | 22.44% |
| Earnings before Tax (EBT) 1 | - | - | 169.1 | 201.1 | 306.5 | 434.3 | 484 |
| Net income 1 | 72.46 | 105.7 | 155.9 | 194 | 277 | 388 | 440 |
| Net margin | 20.86% | - | 23.05% | 20.34% | 21.99% | 23.46% | 20.36% |
| EPS 2 | - | 1.079 | 1.393 | 1.730 | 2.480 | 3.963 | 3.930 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.4286 | 0.1650 | 0.6900 | 0.9100 | 1.210 |
| Announcement Date | 5/31/21 | 2/27/22 | 2/9/23 | 2/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 18.9% | 20.1% | 22% | 23.8% | 24% |
| ROA (Net income/ Total Assets) | - | - | 10.5% | 11.6% | 10.6% | 12.3% | 12.7% |
| Assets 1 | - | - | 1,490 | 1,669 | 2,608 | 3,161 | 3,476 |
| Book Value Per Share 2 | - | - | 8.010 | 9.310 | 11.30 | 16.70 | 16.40 |
| Cash Flow per Share 2 | - | - | 0.9300 | 0.8300 | 1.880 | 3.760 | 3.760 |
| Capex 1 | - | - | 104 | 73 | 58 | 49.5 | 73 |
| Capex / Sales | - | - | 15.35% | 7.65% | 4.6% | 2.99% | 3.38% |
| Announcement Date | 5/31/21 | 2/27/22 | 2/9/23 | 2/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
49.4
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.18% | 760M | |
| +46.19% | 56.65B | |
| -6.14% | 39.44B | |
| +39.19% | 39.03B | |
| -6.65% | 26.86B | |
| +12.33% | 26.75B | |
| -21.78% | 19.03B | |
| -0.35% | 12.28B | |
| +24.18% | 12.26B | |
| +28.38% | 12.04B |
- Stock Market
- Equities
- 688621 Stock
- Financials Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
